MGTX MeiraGTx Holdings plc
Financings ·
MeiraGTx will receive up to $400 million from Oberland Capital, starting with $135 million that includes $125 million of royalty funding and a $10 million equity investment. The release does not state the cap multiple on the royalties or the price of the new shares.
MeiraGTx also agreed to a one-time $50,000,000 contingent payment and mid-teens royalties starting on or after July 1, 2029. The 8-K also reports an amendment with Hologen.
MeiraGTx will pay Johnson & Johnson $25 million in cash upfront for bota-vec, a gene therapy whose Phase 3 primary endpoint did not reach statistical significance. The company plans filings in the U.S., EU and Japan, with a potential launch in 2027.
MeiraGTx (Nasdaq: MGTX) moved the maturity of its Perceptive notes from August 2, 2026 to May 2, 2027. It will redeem $25,000,000 by June 30, 2026, and Perceptive's warrants are repriced to $8.00.
MeiraGTx will pay base rent of $111.00 per square foot a year on a new 14,235 square foot lab at 450 East 29th Street, and it moved to end its current sublease at the same address earlier than scheduled. The 8-K does not say what the total commitment will cost.
MeiraGTx Holdings is a vertically integrated, clinical-stage genetic medicines company. Its clinical programs use targeted local delivery of small doses of genetic medicines to treat inherited and more common conditions. Its late-stage programs include radiation-induced xerostomia, Parkinson's disease and AIPL1-associated retinal dystrophy. Its riboswitch platform uses bespoke synthetic riboswitch technology invented in-house to allow precise, dose-responsive expression of a transgene under the control of oral small molecules. The company is focusing that platform on in vivo delivery of biologic therapeutics such as the metabolic peptides GLP-1, GIP, glucagon, amylin, PYY and leptin, as well as cell therapy for oncology and autoimmune diseases and long-term intractable pain. It operates viral vector production facilities in London, United Kingdom and Shannon, Ireland. In December 2025, its London facility was granted a commercial Manufacturer's and Importer's Authorization by the Medicines and Healthcare products Regulatory Agency for advanced therapy medicinal products. The company has a collaboration, option and license agreement with Johnson & Johnson Innovative Medicine, entered on January 30, 2019.
| Product or program | What it is | Stage |
|---|---|---|
| Radiation-induced xerostomia program | Targeted local genetic medicine for radiation-induced xerostomia | Late-stage clinical |
| Parkinson's disease program | Targeted local genetic medicine for Parkinson's disease | Late-stage clinical |
| AIPL1-associated retinal dystrophy program | Targeted local genetic medicine for AIPL1-associated retinal dystrophy | Late-stage clinical |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $81.4 million | $33.3 million |
| Research and development | $129.6 million | $119.5 million |
| Net income (loss) | -$114.2 million | -$147.8 million |
| Cash from operations | -$46.4 million | -$104.5 million |
| Cash and equivalents | $65.9 million | $103.7 million |
Our latest story on this, dated Apr 16, 2026: "MeiraGTx agrees to buy bota-vec from Johnson & Johnson for $25 million upfront". The story links the filing or release it is based on. Read the story.
MeiraGTx Holdings plc trades under the ticker MGTX on NASDAQ.
MeiraGTx Holdings plc is listed on NASDAQ. Our directory also records these other listings: GETTEX:328; LS:A2JGHF.
The SEC Central Index Key (CIK) for MeiraGTx Holdings plc is 1735438. Its filings are on SEC EDGAR.
96,042,996 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.
Our directory records MeiraGTx Holdings plc under United States.
Our directory classifies MeiraGTx Holdings plc as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for MeiraGTx Holdings plc is KYG596651029.
aibio.space lists MeiraGTx Holdings plc among 2,820 public biotech companies and publishes its news here as stories appear.
MeiraGTx Holdings is a vertically integrated, clinical-stage genetic medicines company. Its clinical programs use targeted local delivery of small doses of genetic medicines to treat inherited and more common conditions.
Radiation-induced xerostomia program: Targeted local genetic medicine for radiation-induced xerostomia Stage: Late-stage clinical.
Parkinson's disease program: Targeted local genetic medicine for Parkinson's disease Stage: Late-stage clinical.
$81.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
MeiraGTx Holdings plc reported a net loss of $114.2 million for the fiscal year ended Dec 31, 2025, and used $46.4 million of cash in operations, per its annual report to the SEC.
$129.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,7.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,7.01,8.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio